Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BDTX stock hub

Black Diamond Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

BDTXis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
171.3M
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
BDTX
In the news

Latest news · BDTX

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROE-35.2
P25 -105.6P50 -46.5P75 -3.1
ROIC-20.4
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All BDTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
185
Groups with data
11
Currency
USD
Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

24
MetricValue
Cik
0001701541
Company name
Black Diamond Therapeutics, Inc.
Country
United States
Country code
US
Cusip
09203E105
Employees
21
Employees Change
-3%
Employees Change Percent
-12.5
Enterprise value
$67.2M
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2020-01-30
Isin
US09203E1055
Last refreshed
2026-05-10
Market cap
$171.3M
Market cap category
Micro-Cap
Price
$2.99
Price currency
USD
Sector
Healthcare
Sic
2836
Symbol
BDTX
Website
https://www.blackdiamondtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

3
MetricValue
Earnings Yield
-25.22%
FCF yield
-19.86%
P/B ratio
1.64x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

10
MetricValue
Net Income
$-43.2M
Net Income Growth Years
4%
Profit Per Employee
$-2.1M
Profitable Years
1
ROA
-18.57
Roa5y
-23.24
ROCE
-38.79
ROE
-35.16
Roe5y
-45.22
ROIC
-20.39

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

5
MetricValue
Cagr1y
92.99%
Cagr3y
14.92%
Cagr5y
-34.87%
EPS Growth Years
4
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

17
MetricValue
Assets
$132.9M
Cash
$118.3M
Current Assets
$123M
Current Liabilities
$14.5M
Debt
$14.1M
Debt Equity
$0.14
Equity
$104.3M
Liabilities
$28.6M
Long Term Assets
$10M
Long Term Liabilities
$14.1M
Net Cash
$104.2M
Net Cash By Market Cap
$60.8
Net Cash Growth
-20.37%
Net Debt Equity
$-1
Tangible Book Value
$104.3M
Tangible Book Value Per Share
$1.82
WACC
20.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

4
MetricValue
Current ratio
8.46
Net Working Capital
$-9.8M
Quick ratio
8.14
Working Capital
$108.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-0.91%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

40
MetricValue
1Y total return
92.9%
200-day SMA
2.94
3Y total return
51.78%
50-day SMA
2.5
50-day SMA vs 200-day SMA
50under200
5Y total return
-88.27%
All Time High
46.25
All Time High Change
-93.54%
All Time High Date
2020-06-03
All Time Low
1.18
All Time Low Change
153.39%
All Time Low Date
2022-10-17
ATR
0.22
Beta
3.34
Beta1y
2.45
Beta2y
2.32
Ch YTD
23.05
High
3.15
High52
4.94
High52 Date
2025-11-12
High52ch
-39.47%
Low
2.7
Low52
1.53
Low52 Date
2025-05-08
Low52ch
95.17%
Ma50ch
19.46%
Premarket Change Percent
0.74
Premarket Price
$2.74
Premarket Volume
2,378
Price vs 200-day SMA
1.7%
RSI
58.76
RSI Monthly
47.25
RSI Weekly
55.13
Sharpe ratio
1.21x
Sortino ratio
1.85
Total Return
-0.91%
Tr YTD
23.05
Tr1m
22.04%
Tr1w
15%
Tr3m
32.59%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

12
MetricValue
Analyst Count
7
Analyst Count Top
4
Analyst Price Target Top
$9
Analyst Ratings
Strong Buy
Analyst Ratings Top
Strong Buy
Earnings EPS Estimate
$-0.21
Earnings Revenue Estimate
30,000,000x
Earnings Revenue Estimate Growth
-57.14x
Operating Income
$-45.9M
Price target
$9.67
Price Target Change
$223
Price Target Change Top
$201

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

10
MetricValue
Float
46,259,580%
Float Percent
80.73%
Shares Insiders
0.67%
Shares Institutions
58.08%
Shares Out
57,301,774
Shares Qo Q
0.25%
Shares Yo Y
0.91%
Short Float
11.83%
Short Ratio
8.5
Short Shares
9.55

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

58
MetricValue
Adjusted FCF
$-40.4M
Average Volume
954,887.55x
Bv Per Share
1.82
Ch1m
22.04
Ch1w
15
Ch1y
92.9
Ch3m
32.59
Ch3y
51.78
Ch5y
-88.27
Ch6m
-23.14
Change
9.93%
Change From Open
9.93
Close
2.72
Days Gap
0
Depreciation Amortization
265,000
Dollar Volume
4,973,204.2
Earnings Date
2026-05-07
Earnings Time
bmo
EBIT
$-45.9M
EBITDA
$-45.7M
EPS
$-0.76
F Score
1
FCF
$-34M
FCF EV Yield
-50.67x
FCF Per Share
$-0.59
Financing CF
-363,000
Fiscal Year End
December
Founded
2,014
Investing CF
-33,952,000
Ipr
-84.26
Iprfo
-90.94
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-05-07
Last Report Date
2026-03-31
Last Split Type
Never
Last10k Filing Date
2026-03-16
Ma150
2.93
Ma150ch
2.15%
Ma20
2.87
Ma20ch
4.18%
Net CF
-68,343,000
Next Earnings Date
2026-08-06
Open
2.72
Optionable
Yes
Position In Range
64.44
Post Close
2.99
Postmarket Change Percent
1.34
Postmarket Price
$3.03
Ppne
9,095,000
Pre Close
2.72
Price Date
2026-05-08
Ptbv Ratio
1.64
Relative Volume
1.74x
Share Based Comp
6,375,000
Tr6m
-23.14%
Us State
Massachusetts
Volume
1,663,279
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does BDTX pay a dividend?

Capital-return profile for this ticker.

Performance

BDTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+92.9%
S&P 500 1Y: n/a
3Y total return
+51.8%
S&P 500 3Y: n/a
5Y total return
-88.3%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns BDTX?

Insider, institutional, and short-interest positioning.

Institutional ownership
+58.1%
Float: +80.7% of shares outstanding
Insider ownership
+0.7%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+11.8%
8.5 days to cover
Y/Y dilution
+0.9%
Negative means the company is buying back shares.
Technical

BDTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
58.8
Neutral momentum band
Price vs 200-day MA
+1.7%
50/200-day relationship not available
Beta (5Y)
3.34
More volatile than the market
Sharpe ratio
1.21
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About BDTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BDTX stock rating?

Black Diamond Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BDTX analysis?

The full report lives at /stocks/BDTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BDTX?

The latest report frames BDTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BDTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.